Rosetta Genomics Company Executives
| ROSGQ Stock | USD 0.0001 0.00 0.00% |
Rosetta Genomics employs about 86 people. The company is managed by 5 executives with a total tenure of roughly 11 years, averaging almost 2.0 years of service per executive, having 17.2 employees per reported executive. Discussion of Rosetta Genomics' management performance can provide insight into the enterprise performance.
| Eti Meiri President Vice President - Research |
| Douglas Sites President Executive Vice President - Sales and Marketing |
Rosetta |
Rosetta Genomics Management Team Effectiveness
The company has return on total asset (ROA) of (0.6019) % which means that it has lost $0.6019 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.3796) %, meaning that it generated substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.Rosetta Genomics Workforce Comparison
Rosetta Genomics is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 191. Rosetta Genomics totals roughly 86.0 in number of employees claiming about 45% of equities under Health Care industry.
Rosetta Genomics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Rosetta Genomics Price Series Summation is a cross summation of Rosetta Genomics price series and its benchmark/peer.
Rosetta Genomics Notable Stakeholders
A Rosetta Genomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Rosetta Genomics often face trade-offs trying to please all of them. Rosetta Genomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Rosetta Genomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Eti Meiri | Vice President - Research | Profile | |
| Douglas Sites | Executive Vice President - Sales and Marketing | Profile | |
| Ayelet Hajt | Head RD | Profile | |
| Pr MD | Deputy Board | Profile | |
| Mark Willig | Chief Officer | Profile |
About Rosetta Genomics Management Performance
The success or failure of an entity such as Rosetta Genomics often depends on how effective the management is. Rosetta Genomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rosetta management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rosetta management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 86 people.
Rosetta Genomics Workforce Analysis
Traditionally, organizations such as Rosetta Genomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Rosetta Genomics within its industry.Rosetta Genomics Manpower Efficiency
Return on Rosetta Genomics Manpower
| Revenue Per Employee | 107.4K | |
| Revenue Per Executive | 1.8M | |
| Net Loss Per Employee | 188.8K | |
| Net Loss Per Executive | 3.2M |
Additional Tools for Rosetta Pink Sheet Analysis
When running Rosetta Genomics' price analysis, check to measure Rosetta Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rosetta Genomics is operating at the current time. Most of Rosetta Genomics' value examination focuses on studying past and present price action to predict the probability of Rosetta Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rosetta Genomics' price. Additionally, you may evaluate how the addition of Rosetta Genomics to your portfolios can decrease your overall portfolio volatility.